1.04
0.95%
-0.01
Pre-mercato:
1.04
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché CHRS Giù?
Forum
Previsione
Coherus Biosciences Inc Borsa (CHRS) Ultime notizie
Coherus BioSciences, Inc. (CHRS): Worst 52-Week Low Stock to Buy Now - Yahoo Finance
Wall Street SWOT: Coherus Biosciences stock faces headwinds amid market challenges - Investing.com
Junshi wins European approval for cheaper checkpoint blocker - The Pharma Letter
Short Interest Surges to 21.83% as Coherus BioSciences, Inc. (CHRS) Faces Revenue Challenges - Insider Monkey
Short Interest Surges to 21.83% as Coherus BioSciences, Inc. (CHRS) Faces Revenue Challenges - Yahoo Finance
CHRS stock touches 52-week low at $1.01 amid market challenges - Investing.com India
Revenues Working Against Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Share Price Following 27% Dive - Simply Wall St
CHRS (Coherus BioSciences) Debt-to-EBITDA : -10.54 (As of Jun. 2024) - GuruFocus.com
Institutional owners may take dramatic actions as Coherus BioSciences, Inc.'s (NASDAQ:CHRS) recent 12% drop adds to one-year losses - Yahoo Finance
HC Wainwright Weighs in on Coherus BioSciences, Inc.'s FY2028 Earnings (NASDAQ:CHRS) - MarketBeat
Coherus shares stumble on supply issue - The Pharma Letter
HC Wainwright Comments on Coherus BioSciences, Inc.'s FY2024 Earnings (NASDAQ:CHRS) - MarketBeat
Baird maintains Coherus outperform stock rating on recent supply hiccup By Investing.com - Investing.com Australia
Coherus BioSciences, Inc. (NASDAQ:CHRS) Has Found A Path To Profitability - Simply Wall St
Baird maintains Coherus outperform stock rating on recent supply hiccup By Investing.com - Investing.com Canada
Baird maintains Coherus outperform stock rating on recent supply hiccup - Investing.com
Coherus BioSciences (NASDAQ:CHRS) Earns Buy Rating from HC Wainwright - MarketBeat
Coherus BioSciences faces UDENYCA supply disruption - Investing.com
Coherus BioSciences, Inc. (NASDAQ:CHRS) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Coherus BioSciences (NASDAQ:CHRS) Downgraded to "Hold" at StockNews.com - MarketBeat
Coherus BioSciences, Inc. (NASDAQ:CHRS) Short Interest Up 6.0% in August - MarketBeat
Coherus BioSciences (NASDAQ:CHRS) Upgraded to Buy by StockNews.com - MarketBeat
CHRS (Coherus BioSciences) Enterprise Value : $254.6 Mil (As of Aug. 19, 2024) - GuruFocus.com
CHRS stock touches 52-week low at $1.22 amid market challenges - Investing.com
CHRS stock touches 52-week low at $1.22 amid market challenges - Investing.com UK
CHRS (Coherus BioSciences) Dividends per Share : $0.00 (TTM As of Jun. 2024) - GuruFocus.com
UBS Downgrades Coherus BioSciences (CHRS) - MSN
UBS cuts Coherus to neutral, cites limited growth opportunities - MSN
Coherus BioSciences (NASDAQ:CHRS) Stock Rating Lowered by UBS Group - MarketBeat
Coherus BioSciences (NASDAQ:CHRS) Downgraded by UBS Group - Defense World
UBS cuts Coherus shares target amid concerns over future revenue growth - Investing.com
Coherus BioSciences, Inc. (NASDAQ:CHRS) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Coherus BioSciences, Inc. (NASDAQ:CHRS) Receives Consensus Recommendation of “Moderate Buy” from Analysts - Defense World
Evaluating Coherus BioSciences: UDENYCA’s Sucess And LOQTORZI’s Prospects (NASDAQ:CHRS) - Seeking Alpha
Vanguard Group Inc. Has $24.09 Million Stock Position in Coherus BioSciences, Inc. (NASDAQ:CHRS) - Defense World
Coherus BioSciences Second Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
Coherus BioSciences, Inc. (CHRS) Q2 2024 Earnings Call Transcript - Seeking Alpha
Coherus BioSciences: Q2 Earnings Snapshot - CTPost
A quintet of CFO hires at Intra-Cellular, Engrail, Faron, Coherus and Element - BioCentury
Coherus BioSciences: Q2 Earnings Snapshot - Houston Chronicle
Coherus BioSciences: Q2 Earnings Snapshot - San Antonio Express-News
Coherus BioSciences (CHRS) Reports Q2 Loss, Tops Revenue Estimates - MSN
Coherus BioSciences Reports Second Quarter 2024 Financial Results and Provides Business Update - BioSpace
Coherus BioSciences (CHRS) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Canada Finance
Coherus Biosciences Appoints Bryan McMichael as CFO - TipRanks
Coherus BioSciences: Q2 Earnings Snapshot - The Bakersfield Californian
Coherus BioSciences Reports Second Quarter 2024 Financial Results and Provides Business Update - StockTitan
Coherus BioSciences Reports Second Quarter 2024 Financial Results and Provides Business Update - GlobeNewswire
Why Investors Shouldn't Be Surprised By Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Low P/S - Simply Wall St
Coherus BioSciences (CHRS) to Release Earnings on Thursday - Defense World
Virtu Financial LLC Buys New Position in Coherus BioSciences, Inc. (NASDAQ:CHRS) - Defense World
Public Employees Retirement Association of Colorado Sells 9,197 Shares of Coherus BioSciences, Inc. (NASDAQ:CHRS) - Defense World
Public Employees Retirement Association of Colorado Sells 9,197 Shares of Coherus BioSciences, Inc. (NASDAQ:CHRS) - American Banking and Market News
Coherus BioSciences' (CHRS) Buy Rating Reaffirmed at HC Wainwright - MarketBeat
HC Wainwright Reiterates Buy Rating for Coherus BioSciences (NASDAQ:CHRS) - Defense World
Bayesian Capital Management LP Makes New $56,000 Investment in Coherus BioSciences, Inc. (NASDAQ:CHRS) - Defense World
Coherus BioSciences (CHRS) Set to Announce Quarterly Earnings on Thursday - MarketBeat
SG Americas Securities LLC Decreases Position in Coherus BioSciences, Inc. (NASDAQ:CHRS) - Defense World
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Capitalizzazione:
|
Volume (24 ore):